Viridian Therapeutics Inc VRDN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
-
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
-
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
-
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
Trading Information
- Previous Close Price
- $23.06
- Day Range
- $22.91–23.76
- 52-Week Range
- $10.93–24.18
- Bid/Ask
- $23.33 / $23.96
- Market Cap
- $1.78 Bil
- Volume/Avg
- 1.4 Mil / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4,424.43
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 94
Comparables
Valuation
|
Metric
|
VRDN
|
FATE
|
VERA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.52 | 1.02 | 7.26 |
Price/Sales | 4,424.43 | 30.13 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VRDN
|
FATE
|
VERA
|
|---|---|---|---|
Quick Ratio | 15.54 | 8.79 | 20.98 |
Current Ratio | 15.82 | 9.18 | 21.43 |
Interest Coverage | −92.88 | — | −19.84 |
Quick Ratio
VRDN
FATE
VERA
Profitability
|
Metric
|
VRDN
|
FATE
|
VERA
|
|---|---|---|---|
Return on Assets (Normalized) | −34.35% | −24.79% | −35.17% |
Return on Equity (Normalized) | −64.16% | −33.35% | −45.77% |
Return on Invested Capital (Normalized) | −41.62% | −30.13% | −40.21% |
Return on Assets
VRDN
FATE
VERA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gxfvwbvxf | Dgnf | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jqhngmqf | Kyygcy | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qktplyzs | Stddjr | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nnlnsrkwv | Wrjnzw | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Rzykwfwy | Mjt | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Xxfhrkqm | Pbfbb | $28.1 Bil | |||
| Moderna Inc
MRNA
| Qkpbdwz | Qgzqv | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Htlmvvtk | Dwxr | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Thhmnksz | Dspbdgm | $13.4 Bil | |||
| Incyte Corp
INCY
| Pnqhsdyqg | Vdhzpt | $12.7 Bil |
United States